|1.||Endo, Shunro: 2 articles (12/2005 - 02/2002)|
|2.||Hirashima, Yutaka: 2 articles (12/2005 - 02/2002)|
|3.||Garg, Bhavuk: 1 article (11/2014)|
|4.||Gupta, Sumit: 1 article (11/2014)|
|5.||Kishimoto, Shun: 1 article (10/2013)|
|6.||Yukimasa, Ogino: 1 article (10/2013)|
|7.||Fukami, Norihiko: 1 article (10/2013)|
|8.||Nakamura, Kumi: 1 article (10/2013)|
|9.||Arai, Toshiyuki: 1 article (10/2013)|
|10.||Kumihashi, Mitsuru: 1 article (07/2011)|
|2.||Hypertension (High Blood Pressure)
02/01/1992 - "These results allow us to conclude that etizolam is effective and safe for the treatment of essential hypertension accompanied with unspecified complaints."
02/01/1992 - "We assessed the efficacy of etizolam (an antianxiety drug) in 18 patients with essential hypertension accompanied with unspecified complaints. "
02/01/1992 - "The efficacy of additive use of etizolam in patients with essential hypertension and unspecified complaints."
|3.||Anxiety Disorders (Anxiety Disorder)
12/01/2009 - "The primary aim of this study was to test for the noninferiority of etizolam 0.5 mg BID versus placebo in affecting cognitive function in patients with mild to moderate anxiety disorder of recent onset (<1 month). "
01/01/1990 - "A double-blind, placebo-controlled study was carried out in 36 patients diagnosed as suffering from Generalized Anxiety Disorder with associated depressive symptoms to assess the efficacy and tolerability of two unitary doses of etizolam. "
11/01/2014 - "We report a case of etizolam dependence in a young male with social anxiety disorder and moderate depression. "
12/01/2009 - "Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder."
01/01/1990 - "Etizolam in the treatment of generalized anxiety disorder: a double-blind study versus placebo."
08/01/1987 - "Injection of PAF into the tail veins of mice produced lethal shock within 10-30 min. Etizolam (0.1-3 mg/kg, i.v. and 1-10 mg/kg, p.o.) protected against the lethal effect of PAF (75 micrograms/kg, i.v.) in a dose-dependent manner. "
02/01/1999 - "Further, etizolam inhibited in a dose-dependent manner basal acetylcholine release from both hippocampus and prefrontal cortex, and reversed foot-shock-induced increase of basal acetylcholine release to a control level. "
12/01/1995 - "Rhesus monkeys (n = 3), trained to discriminate pentobarbital (PB; 10 mg/kg, IG) from saline under a discrete-trials shock avoidance procedure, were given IG diazepam (0.3-10 mg/kg), chlordiazepoxide (1.0-30 mg/kg), or etizolam (0.3-10 mg/kg) alone and in combination with flumazenil (0.01-1.7 mg/kg, IM). "
|5.||Panic Disorder (Panic Attack)
01/01/1990 - "Thirty out-patients suffering from panic disorders associated with agoraphobia were enrolled in a double-blind, controlled trial to compare the effectiveness and tolerability of etizolam and placebo. "
01/01/1990 - "Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study."
11/01/2002 - "A 41-year-old man with panic disorder had been treated with alprazolam 1.2 mg/d (3 times daily), carvedilol 10 mg/d (once in the morning), and etizolam 0.5 mg (for anxiety attack). "
|1.||Antipsychotic Agents (Antipsychotics)
|10.||Platelet Activating Factor